A Phase 1, Open-Label, Single-Center Study Evaluating Absolute Bioavailability, Safety and Tolerability of Subcutaneous Formulation of RYI-018 Compared to Intravenous Formulation in Overweight and Obese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Namacimab (Primary) ; Namacimab
- Indications Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Bird Rock Bio
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.
- 19 Nov 2018 Recruitment completion is expected on 22 Nov 2018 according to Australian New Zealand Clinical Trials Registry.
- 22 Sep 2018 New trial record